Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 0 · 0%High 1 · 50%

Overall survival† · people with cutaneous melanoma

MEK inhibitors showed no clear difference in overall survival† compared with chemotherapy (low certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.85 [0.58, 1.25]
496 participants
Low

Overall survival† · people with cutaneous melanoma

BRAF plus MEK inhibitors leads to lower overall survival† compared with BRAF inhibitors (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.7 [0.59, 0.82]
1784 participants
High